Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer—Gynaecological Cancer Group)

Background: No standard treatment options are available for patients with advanced, recurrent or metastatic vulvar carcinoma not amenable for locoregional treatment. Patients and methods: In this phase II study, patients with advanced vulvar cancer received paclitaxel (Taxol) every 3 weeks for up to...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Witteveen, P. O., van der Velden, J., Vergote, I., Guerra, C., Scarabeli, C., Coens, C., Demonty, G., Reed, N.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2009
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2731017/
https://ncbi.nlm.nih.gov/pubmed/19487487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdp043
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars